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Introduction
Currently, cardiovascular diseases (CVDs) account for two-
thirds of the total non-communicable disease (NCD) burden in 
India1. According to the 2016 Global Burden of Disease study, 
ischemic heart disease was the leading cause of the Disability-
adjusted life years (DALYs), measured to be 3062 per 100,000 
population in India2. Also, the all-age death rate increased sig-
nificantly between 1990 and 2016 for ischaemic heart disease 
(percentage change 54·5%), and CVDs are the leading cause 
of death in most parts of India2,3. Indians are affected by CVDs 
at a younger age compared to their European counterparts, with 
more than 50% CVDs deaths occurring before the age of 704–6. 
The World Health Organization (WHO) had estimated that, 
due to the burden of CVDs, India had lost 237 billion dollars 
over ten years (2005–2015)7.
CVDs risk approach is a cost-effective means to identify those 
at high risk so that immediate short and long-term preventive 
steps can be followed to mitigate the risk8. Risk stratifica-
tion approach has been primarily found to be cost-effective in 
resource-poor settings9.
Although risk factor effect can be similar across populations, 
the estimated cardiovascular disease risk from risk models 
differs substantially across populations. This is mainly because 
of the different “baseline incidence of the risk model outcome” 
and prevalence of the different risk factors across populations. 
Also, a meta-analysis based on 17 population-based cohorts 
worldwide has shown that ethnicity modifies the association 
between risk factors and cardiovascular disease10. Another 
study from the United Kingdom has shown the CVD risk 
prediction model to be inaccurate in the South Asian group 
as compared to white Europeans11. Studies have also proved 
that the Framingham risk prediction model underestimates the 
CVD risk in Asian Indians and socioeconomically deprived 
individuals12,13.
The Framingham risk equation is a well-established and widely 
used method to measure coronary heart disease (CHD) risk, 
but was developed with a white US-based population several 
decades ago and so, there is a need to re-calibrate it when 
applying it in other populations. Recalibrating a risk equation to 
a new population involves estimating the average values of the 
risk factors and the average risk of CVD. These values are used 
as the reference values in the risk model equations. To the best of 
our knowledge, only one study has recalibrated the Framingham 
risk equation in India, and this was for a rural population14. 
As there is no validated prognostic model for an Indian urban 
population, we have re-calibrated the original Framingham 
model. In this paper, we report the Framingham model rec-
alibration to an Indian urban population using data from two 
studies: CARRS (Centre for cArdiometabolic Risk Reduction in 
South-Asia), and ICMR (Indian Council of Medical Research). 
We compare the 10-year predictions of CVD fatal and non- 
fatal events produced by the original Framingham model and 
the recalibrated models and describe the potential impact of 
the recalibration on the proportion of the population eligible 
for treatment as recommended by current WHO guidelines.
Methods
Data sources
We used data from two studies:
a)    The CARRS Cohort study was a population-based sam-
ple of urban adults in Chennai, New Delhi and Karachi 
established to assess the prevalence and incidence of 
cardio-metabolic diseases and their risk factors. Its 
details have been published previously15, in brief, par-
ticipants were selected in each city using multi-stage 
cluster random sampling with the Kish method16 to 
select only one man and one woman aged 20+ from each 
randomly selected household. Here we used baseline 
data from the cross-sectional survey conducted between 
October 2010, and December 2011 with mortality follow 
up through June 2014.
b)    The ICMR study was a cross-sectional survey conducted 
to estimate CVD risk factor prevalence in the National 
Capital Region of India (Delhi and Ballabgarh) in 
2010–201217. Multi-stage cluster random sampling was 
used for the primary sampling unit (household) selection. 
Data were collected on sociodemographic characteristics, 
CVD risk factors, treatment status, and measurements 
of height, weight, hip and waist circumference, and blood 
pressure. Fasting blood glucose (FBG) and lipids meas-
urements were done using fasting venous blood. Here 
we have included data only from the urban area of Delhi.
Risk calculation
Below we described the different steps we conducted to recalibrate 
the Framingham score
Step 1: Framingham score calculation (i.e. Xi): We first 
calculated each individual Framingham “score” for CVD events 
in the next 10 years. This is a weighted sum of the individual’s 
characteristics using the Framingham weights (see Table 1).
Step 2: Reference individual survival calculation (S0): We 
then obtained the 2012 yearly mortality rates from CHD 
causes for India from WHO (0.003489 for men and 0.002646 
for women). We assumed that the ratio of non-fatal to fatal 
events was 2:1 so the yearly rates of total fatal and non-fatal 
Table 1. Coefficients from simplified 
Framingham model.
MEN WOMEN
Log of Age 3.11296 2.72107
Log of Body Mass Index 0.79277 0.51125
Log of SBP* if not treated 1.85508 2.81291
Log of SBP if treated 1.92672 2.88267
Smoking (0=No / 1=Yes) 0.70953 0.61868
Diabetes (0=No / 1=Yes) 0.53160 0.77763
* SBP: systolic blood pressure.
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events was estimated as 3*0.003489 = 0.010467 for men 
and 3*0.002646 = 0.007938 for women. We assumed a con-
stant ratio, and therefore the probabilities of not having events 
in 10-years were (1 – 0.010467)10 = 0.90013 for men and 
(1 – 0.007938)10 = 0.923396 for women.
Step 3: Reference individual score calculation (X0): We then 
calculated three risks for each individual considering different 
values of scores and survivals: M1) using Framingham’s 
reference score and survival, M2) using a reference score (X0) 
derived from CARRS and estimated survival (S0) derived 
from WHO 2012 data for India (see above), and M3) using 
reference score (X0) derived from ICMR and the estimated 
survival (S0) derived from WHO 2012 data for India. We 
estimated the score of the “average individual” in the popula-
tion by multiplying the averages of the variables (in the log 
scale for the continuous variables) by the original Framingham 
coefficients and adding the values for all risk factors.
Step 4: Estimation of risks with different models: We calcu-
lated the risks for everyone in the CARRS and the ICMR datasets 
with three models (M1, M2, M3) using different combinations 
of reference score (X0) and survival probabilities (S0).
Comparison of risk and treatment
With each of the three risk calculations (M1. M2 and M3), we 
have stratified individuals in three different risk categories 
(<10%, 10–30%, and >30) which are commonly used for treat-
ment recommendations for antihypertensive and statins. To see 
how recalibration with one or another data set affects the propor-
tion of individuals treated, we have compared the proportion of 
individuals in the third risk category (>30%) between the 
different models. We reported the study following the TRIPOD 
statement18. A completed TRIPOD statement is available from 
OSF19. We used statistical package R, version 3.5.1 (2018-07-02)[1] 
for all our analysis
Results
Population characteristics
The CARRS study had data from 16,287 participants, but 
only 11,407 of those had the data needed to calculate the 
Framingham risk score (5,151 men and 6,256 women). The 
ICMR study had 3,075 individuals, but only 2,401 had all the data 
needed to calculate the score (1,089 men and 1,312 women).
In Table 2 we show the summaries statistics for each of the vari-
ables used in the Framingham score calculated in all the individuals 
that provided data for each variable separately.
In Table 3 below we report the reference scores using the 
Framingham, CARRS and ICMR populations, for this we have 
used the means of the log of the variables (which is not the 
same as the log of the mean). For example, for age, we first calcu-
lated a new variable “log(age)” for every single individual. Then 
we calculated the mean of this mean Mean[log(age)] =3.72033. 
Table 4 shows an example of the calculations using the 
CARRS population means.
Figure 1 shows the distribution of the recalibrated Framingham 
scores by sample and sex. Women have on average higher scores 
than men, and the Framingham ICMR recalibrated score has 
slightly higher means than the Framingham CARRS recalibrated 
in each sex.
Finally, in Table 5 we summarize the risk of the participants 
in both, CARRS and ICMR, estimated with the three different 
models for each sex/cohort. We present the mean risk and the 
distribution of the individuals in the three risk categories stated 
above (0–10%, 10–30%, and > 30%).
Effect of the recalibrated prognostic model on treatment
According to the WHO guidelines individuals with a risk of 
fatal or non-fatal cardiovascular event > 30% should get treat-
ment with statins20. In Figure 2 below we plot the difference in 
the proportion of individuals (by sex and cohort) that should 
be eligible for treatment according to the different models. 
For example, as shown in the red bar to the top-left graph of 
Figure 2, if we used model M2 instead of M1, about 8% more 
men in CARRS will be eligible for treatment. This can be calcu-
lated from the difference of 21.0% – 13.3% in Table 5 (first two 
rows for men). The pattern is very similar in both datasets within 
each sex. In men model M2 increases the proportion of men 
Table 2. Descriptive of risk factors in the two data sets *: mean (standard deviation).
MEN WOMEN
Data CARRS ICMR All CARRS ICMR All
Age* 43.5 (14.0) 47.2 (13.0) 44.1 (13.9) 41.4 (12.6) 45.2 (13.0) 42.0 (12.8)
BMI* 24.3 (4.6) 24.7 (6.1) 24.3 (4.9) 26.5 (5.5) 26.5 (5.5) 26.5 (5.5)
SBP*untreated 125.0 (17.8) 129.9 (19.4) 125.7 (18.1) 116.6 (18.0) 122.3 (19.6) 117.5 (18.4)
SBP*treated 139.5 (21.5) 143.9 (23.8) 140.4 (22.1) 136.7 (23.9) 143.6 (24.5) 138.2 (24.2)
Treatment 10.0% 13.8% 10.6% 14.7% 19.0% 15.4%
Smokers 26.8% 28.8% 27.1% 1.6% 3.3% 1.9%
Diabetics 27.2% 12.5% 24.6% 26.4% 10.7% 23.4%
BMI: body mass index, SBP: systolic blood pressure
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Table 4. Example of reference score calculations using means from 
CARRS population.
MEN WOMEN
Coefficient * mean Coefficient * Mean
Log of Age 3.11296*3.72033 2.72107*3.67602
Log of Body Mass Index 0.79277*3.17187 0.51125*3.25623
Log of SBP if untreated 1.85508*4.81871*0.8975 2.81291*4.74785*0.8553
Log of SBP if treated 1.92672*4.92633*0.1025 2.88267*4.90344*0.1447
Smoking 0.70953*0.26817 0.61868*0.01607
Diabetes 0.53160*0.27187 0.77763*0.26391
Sum SM = 23.42494 SW = 25.35218
Figure 1. Box-plots of the distribution of the Framingham scores by sex and study. CARRS: Centre for cArdiometabolic Risk Reduction 
in South-Asia; ICMR: Indian Council of Medical Research.
Table 3. Reference scores using Framingham, 
CARRS and ICMR populations and reference 








WHO 2012 0.90013 0.92340
CARRS: Centre for cArdiometabolic Risk Reduction in 
South-Asia; ICMR: Indian Council of Medical Research; 
WHO: World health organization
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Figure 2. Difference in the proportion of treated individuals (risk > 30%) between the estimation of the three methods (M2-M1, M3-M1, 
and M2-M3). Bars reach the difference in proportions and segments represent 95% confidence intervals for the difference. M-1) Framingham 
M-2) F-CARRS recalibrated and M-3) F- ICMR recalibrated. F: Framingham; CARRS: Centre for cArdiometabolic Risk Reduction in South-Asia; 
ICMR: Indian Council of Medical Research
Table 5. Means of estimated risks and distribution by risk categories of individuals 
in each cohort with different estimation models: M-1) Framingham M-2) F-CARRS 
recalibrated and M-3) F- ICMR recalibrated. F: Framingham; CARRS: Centre for 
cArdiometabolic Risk Reduction in South-Asia; ICMR: Indian Council of Medical Research.
MEN WOMEN
Data/model Mean <=10% 10–30% >30% Mean <=10% 10–30% >30%
CARRS participants:
M1) Framingham 0.138 56.7% 30.0% 13.3% 0.063 81.1% 15.4% 3.5%
M2) F-CARRS 0.182 47.0% 32.0% 21.0% 0.150 60.1% 23.5% 16.4%
M3) F-ICMR 0.140 56.2% 30.2% 13.6% 0.118 66.6% 21.8% 11.6%
ICMR participants:
M1) Framingham 0.155 53.4% 30.6% 16.0% 0.079 76.5% 17.9% 5.6%
M2) F-CARRS 0.204 43.4% 32.4% 24.2% 0.183 52.5% 27.0% 20.5%
M3) F-ICMR 0.157 53.0% 30.5% 16.5% 0.145 60.6% 24.1% 15.3%
that should be treated compared to both model M1 and model 
M3, and M1 and M3 categorize men very similarly. For women, 
models M2 and M3 also increase the proportion of women that 
should be treated in comparison to M1, but in addition model, 
M2 also categorize more women than M3 as eligible to be treated.
Discussion
In this study, we calculated the 10-year Framingham CVD 
score in two cohorts of Indian urban populations (CARRS and 
ICMR) by using coefficients from a simplified Framingham 
model. We then predicted the risk in each cohort using three 
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different models: one with the original Framingham reference 
coefficients and two recalibrated with the average risk factors 
prevalence in each of the datasets and the CHD mortality 
estimations for India from WHO-2012 data.
The average 10-year CVD risk estimates calculated using the 
Framingham recalibrated equation with the CARRS data was 
substantially higher than the original Framingham equation 
for both men and women, but the recalibrated equation using 
the ICMR the averages were only distinctly higher for women 
but not for men. A previous study in rural India, also found 
that the Framingham score underestimates in comparison with 
the one recalibrated with national data14. Other studies in South 
Asian Indian populations have also shown higher CHD incidence 
in comparison to the predicted by Framingham risk score21–24.
The overall CVD risk score is used to inform clinical decisions 
to start treatment to lower blood pressure and statins. The thresh-
olds recommended vary according to the guideline and settings. 
For example, the WHO guidelines recommend that individuals 
with a 30% 10-year risk of a fatal or non-fatal cardiovascular 
event should start with statins. Our study exemplifies that by 
using the prognostic model recalibrated with the CARRS data, 
there will be a substantial increase in the proportion of men 
and women that would be eligible for treatment with statins in 
comparison to the original Framingham risk score. However, 
by using the prognostic model recalibrated with the ICMR 
data, there would only be a substantial increase in the proportion 
of women that would be eligible for treatment.
To the best of the authors’ knowledge, this is the first large com-
munity-based study to recalibrate Framingham risk score in 
an urban population in India. One of our strengths is that the 
data are representative of their respective cities and that we 
used two different cohort studies. The main limitation is that we 
cannot check if the re-classification of the recalibrated model 
is indeed an improvement in risk prediction comparison 
with the original Framingham score because of the lack of 
cardiovascular events in the existing cohorts.
Early identification and initiation of intensive primary preven-
tion among individuals with high risk of CVDs are critically 
important in reducing the CVD burden in India. Although, 
almost all the major recent international guidelines including the 
National Institute for Health and Care Excellence (NICE) 2014 
guidelines, World Health Organization (WHO) 2007 guidelines, 
European Society of Cardiology (ESC) 2016 guidelines and the 
2017 American College of Cardiology (ACC)/American Heart 
Association (AHA) guidelines and national guideline unani-
mously recommend assessment of cardiovascular risk16,25–28, their 
adoption in primary prevention is suboptimal28–30. Few of com-
mon barriers for its decreased use are; lack of national guidelines, 
too many choices for CVD risk score, the uncertainty of validity 
of these risk score model in local context, time-consuming and 
lack of adjustment for the treatment31,32. Recalibrated model based 
on local population can improve the validity of the risk score 
model and reduce the perceived barriers of physician related to 
the local validity and enhance the use of CVD prediction model in 
the clinical setting for primary prevention. However, our study 
shows that even recalibrated models using data from the same 
country could be indeed very different and therefore it is vital to 
recalibrate models applying relevant local data (reflecting as best 
as possible local prevalence and overall mortality data). With the 
increasing use of technology, a possible approach could be to 
develop risk calculators in which local prevalent data and local 
incidence data is easily uploaded, and a “tailored” recalibrated 
model is provided for each setting. However, in the long-term 
future studies should develop CVD prognostic models using 
high quality and well powered local cohorts (with outcome data) 
and evaluate their implementation and impact.
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